Artificial intelligence has earned a firm foothold in drug discovery, helping researchers identify promising compounds and accelerate the earliest stages of bringing new medicines to market. But according to The Pharma Letter, the industry's next significant test for AI may be far less headline-grabbing: the factory floor.
The argument, as The Pharma Letter frames it, is that AI's pharma opportunity is shifting from discovery toward manufacturing — specifically, the challenge of producing more medicines, more reliably, using facilities that already exist. Rather than building new plants from scratch, the focus is on squeezing greater efficiency and consistency out of current infrastructure.
This is a meaningful pivot. Drug manufacturing is notoriously complex, subject to strict regulatory oversight, and prone to costly quality failures that can lead to shortages. Any technology that can reduce variability, predict equipment problems before they cause batch failures, or optimize production schedules stands to have a real-world impact on medicine availability — not just on the speed of new drug development.
The story matters because drug shortages are a persistent public health problem, and the bottleneck is often not a lack of approved medicines but a lack of reliable, scalable manufacturing capacity. If AI can help existing factories run smarter, the benefits could reach patients far sooner than breakthroughs still years away in the discovery pipeline.